Adil Daud, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Adil Daud, MD

HS Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-9900 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Developmental Therapeutics

Education

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine


Professional Experience

  • 1987-1990
    Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
  • 1990-1994
    Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
  • 1994-1997
    Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
  • 1997-2000
    Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2000-2001
    Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2001-2005
    Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Director, Moffitt Clinical Research Network
  • 2008-2010
    Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
  • 2010-present
    HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

Honors & Awards

  • 1986
    Honors in Pediatrics, Government Medical College, Nagpur, India
  • 2000
    Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
  • 2005-2007
    Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
  • 2007-2010
    Best Doctors in America Award, Castle Connolly

Selected Publications

  1. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 Dec; 34(34):4102-4109.
    View on PubMed
  2. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58.
    View on PubMed
  3. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016 Nov; 67:46-54.
    View on PubMed
  4. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies. Cancer. 2016 Aug 17.
    View on PubMed
  5. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 Aug 15.
    View on PubMed
  6. Daud AI. Part I: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 Jun; 8(6):675-6.
    View on PubMed
  7. Daud AI. Part II: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 Jun; 8(7):761-2.
    View on PubMed
  8. Loo K, Daud A. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy. 2016 Jun; 8(7):775-84.
    View on PubMed
  9. Chen L, Daud A. A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. Oncology (Williston Park). 2016 May; 30(5).
    View on PubMed
  10. Daud A, Nandoskar P. Pembrolizumab for melanoma- safety profile and future trends. Expert Opin Drug Saf. 2016 Jun; 15(6):727-9.
    View on PubMed
  11. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9.
    View on PubMed
  12. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30; 374(26):2542-52.
    View on PubMed
  13. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 May 1; 34(13):1510-7.
    View on PubMed
  14. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
    View on PubMed
  15. McElroy LM, Woods DM, Yanes AF, Skaro AI, Daud A, Curtis T, Wymore E, Holl JL, Abecassis MM, Ladner DP. Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical population. Int J Qual Health Care. 2016 Apr; 28(2):166-74.
    View on PubMed
  16. Garrett GL, He SY, Sabouni N, Daud A, Arron ST. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. JAAD Case Rep. 2015 Nov; 1(6):S23-5.
    View on PubMed
  17. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov 1; 151(11):1206-12.
    View on PubMed
  18. Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015; 8(1):123.
    View on PubMed
  19. Daud A. Current and Emerging Perspectives on Immunotherapy for Melanoma. Semin Oncol. 2015 Dec; 42 Suppl 3:S3-S11.
    View on PubMed
  20. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31.
    View on PubMed

Go to UCSF Profiles, powered by CTSI